Version June 2024
| Staging | Total patients (n = 62,212) | 5-Year survival (n = 55,490) |
| I | 3328 (5.3) | 85.6 (84.1–87.0) |
| IA | 2887 (4.6) | 94.1 (93.0–95.0) |
| IA1 | 2812 (4.5) | 95.8 (94.4–96.9) |
| IA2 | 844 (1.4) | 95.0 (92.2–96.7) |
| IB | 1522 (2.4) | 75.9 (73.4–78.2) |
| IB1 | 4480 (7.2) | 91.6 (90.4–92.6) |
| IB2 | 4120 (6.6) | 83.3 (81.8–84.8) |
| IB3 | 3790 (6.1) | 76.1 (74.3–77.8) |
| II | 617 (1.0) | 56.1 (51.4–60.5) |
| IIA | 796 (1.3) | 63.4 (59.5–67.0) |
| IIA1 | 742 (1.2) | 70.3 (65.9–74.3) |
| IIA2 | 1101 (1.8) | 65.3 (61.6–68.6) |
| IIB | 8904 (14.3) | 63.9 (62.7–65.0) |
| III | 407 (0.7) | 39.3 (33.9–44.7) |
| IIIA | 954 (1.5) | 40.7 (37.1–44.3) |
| IIIB | 5177 (8.3) | 41.4 (39.9–42.9) |
| IIIC | 5350 (8.6) | 46.3 (44.8–47.8) |
| IIIC1 | 4625 (7.4) | 60.8 (58.7–62.8) |
| IIIC2 | 1114 (1.8) | 37.5 (33.3–41.7) |
| IVA | 1890 (3.0) | 24.0 (21.7–26.3) |
| IVB | 6752 (10.9) | 14.7 (13.7–15.8) |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
